The preclinical studies of the new vaccine against cancer have given positive results: for this reason the researchers are ready for the next phase, testing it on humans.
The new vaccine was developed by the Mater research team based at the Translational Research Institute in collaboration with the University of Queensland in Australia.
The teacher Kristen Radford, an associate researcher, says that the vaccine has the potential to cure a wide variety of malignancies, and is a very important step forward in fighting cancer in all its manifestations.
“We hope that this cancer vaccine can also be used to treat blood cancers such as myeloid leukemia, non-Hodgkin's lymphoma, multiple myeloma and pediatric leukemias. Not to mention solid tumors like breast, lung, kidney, ovarian and pancreatic cancer, and glioblastoma,” Radford says.
The new cancer vaccine
The new vaccine is composed of human antibodies fused with tumor specific proteins: the next test phase will aim to study its ability to affect human cells by activating the memory of cancer cells.
Professor Radford says the vaccine offers several key advantages over the drugs cancer existing ones that have already shown promising results in the first clinical studies.
This prototype cancer vaccine targets key tumor cells. Those, so to speak, responsible for initiating tumor-specific immune responses. This maximizes the potential effectiveness of the treatment. At the same time, the remedy seems to significantly minimize potential side effects.
“We are very happy to see our research published in a prestigious magazine. I hope our continued work to find a safe and effective cancer vaccine works. We want to benefit cancer patients around the world in the near future.”
